Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JKB-122 Formulations in Healthy Males
NCT04313205Phase 1Unknown
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of naltrexone in autoimmune hepatitis (AIH) (2 arms), sponsored by TaiwanJ Pharmaceuticals Co., Ltd. Primary endpoint: Area under the curve from the time of dosing to steady state at 2 weeks. Status: unknown.
02
Drugs
naltrexone
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT04313205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313205.